Extracellular Matrix Metalloproteinase Inducer Is Increased in Smokers’ Bronchoalveolar Lavage Fluid

Tomoko Betsuyaku, Mishie Tanino, Katsura Nagai, Yasuyuki Nasuhara, Masaharu Nishimura, and Robert M. Senior

First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan, and the Departments of Medicine and Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri

Extracellular matrix metalloproteinase inducer (EMMPRIN), also called basigin, is present in the lung during development, but its expression in normal adult lung is minimal. Increases of EMMPRIN have been found in various forms of experimental lung injury. To determine whether EMMPRIN might be involved in alveolar injury/repair associated with smoking, we developed an ELISA for EMMPRIN and applied it to bronchoalveolar lavage fluids from never-smokers (n = 7), former smokers (n = 16), and current smokers (n = 58). The smoker groups included subjects with emphysema, as determined by high-resolution chest computed tomography. EMMPRIN levels were significantly elevated in current and former smokers (31 ± 20 and 175 ± 15 pg/ml SEM, respectively, compared with 31 ± 7 pg/ml in never-smokers), but the EMMPRIN levels of smokers with emphysema were not different from smokers without emphysema. Immunohistochemistry of smokers’ lung tissue showed EMMPRIN in bronchiolar epithelium and alveolar macrophages, but EMMPRIN mRNA in alveolar macrophages was not different between current and never-smokers. Matrix metalloproteinase-1 was also detectable in the bronchoalveolar lavage fluid from some smokers but not in never-smokers. These findings indicate that smoking is associated with increased intrapulmonary EMMPRIN. Whether EMMPRIN is involved in smoking-induced lung pathology remains to be determined.

Keywords: smoking; emphysema; matrix metalloproteinases; alveolar macrophages

Extracellular matrix metalloproteinase (MMP) inducer (EMMPRIN) is a member of the IgG superfamily (1). EMMPRIN is known by other names: CD147 and M6 in humans; basigin and gp42 in mouse; OX-47 and CE9 in rat; and HT7, neurothelin, and 5A11 in chicken. EMMPRIN is strongly expressed in many tissues during development, including lung (2), but only at low levels in normal adult lung and other tissues (3, 4), suggesting a physiologic role in tissue differentiation and development. EMMPRIN was originally identified on the surface of tumor cells and was termed tumor cell-derived collagenase stimulatory factor (5) because it induced collagenase in adjacent stromal cells (6, 7). Its upregulation in tissues showing increased dissemination of tumor cells with high levels of basigin expression (8). Its upregulation in tissues has been also identified in various nonmalignant conditions, including rheumatoid arthritis (9, 10), chronic liver disease (11), heart failure (12, 13), ischemic myocardial injury (14), atherosclerosis (15), and experimental ventilator-induced lung injury (16).

MMPs are a family of neutral proteinases that degrade extracellular matrix and modify other substrates (17). MMPs have been implicated in various injury and/or repair processes in the lungs (18, 19) and other organs. MMPs are regulated at both pretranscriptional and post-transcriptional levels, and their activities can also be regulated by endogenous inhibitors, including the tissue inhibitors of MMPs, α1-macroglobulin, and reversion-inducing cysteine-rich protein with Kazal motifs (RECK) (20). Because several MMPs are increased in various types of human alveolar pathology (21, 22), we recently investigated the expression of basigin (murine EMMPRIN) after bleomycin. We found basigin in fibroinflammatory areas, increased basigin in bronchoalveolar lavage (BAL) fluids, and basigin mRNA upregulated in bronchiolar epithelial cells (26).

Cigarette smoking is a major risk factor for the development of emphysema. Although the molecular mechanisms linking smoking to the pathogenesis of emphysema have not been fully clarified, MMPs have been implicated in its development (27–30). Therefore, we hypothesized that EMMPRIN may be upregulated in smokers’ lungs and may be involved in the intrapulmonary expression of MMPs associated with smoking. To examine this possibility, we have developed an ELISA for EMMPRIN and have applied it to BAL fluids from never-smokers and smokers. We have observed that EMMPRIN levels are significantly increased in smokers’ BAL fluid compared with never-smokers.

METHODS

Subjects

We recruited 81 volunteers (aged 32–80 years), including 58 current smokers, 16 former smokers who had not smoked for at least 1 year, and 7 individuals who had never smoked. The subjects had no respiratory symptoms and denied acute respiratory infections within the preceding 2 months. The serum α1-antitrypsin concentration was more than 160 mg/dl in all subjects. Measurements of VC, FEV1, and diffusing capacity were performed on all subjects (CHESTAC-55; Chest Co., Tokyo, Japan). High-resolution chest computed tomography scans were performed on all current and former smokers to screen for emphysematous changes, as previously described (31). Three pulmonary physicians who were blinded to any information about the subjects independently evaluated the computed tomography scans for the presence of emphysema. Emphysema was considered present only if all three physicians agreed, regardless of severity. Informed consent was obtained from each subject, and the Ethics Committee of Hokkaido University School of Medicine approved the study.

Sequential BAL and Processing of BAL Fluids

Current smokers were asked to refrain from smoking for at least 12 hours before the BAL procedure to reduce acute effects of smoking. Four separate 50-ml aliquots of sterile 0.9% saline were instilled into a segment of the right middle lobe through a wedged flexible fiberoptic bronchoscope.
bronchoscope (Olympus BF-B3R, Tokyo, Japan) and then gently aspirated. The fluid returned from the first 50-ml aliquot was discarded to reduce the contribution from large airways (32). The fluid from the other three aliquots was combined and filtered through several layers of gauze to remove excess mucus and debris, and a sample was taken for cell count and differential. The fluid was then centrifuged at 1,500 rpm for 5 minutes at 4°C. The cell-free supernatant was aliquoted and stored at −70°C. The albumin concentration was measured as previously described (31).

Quantitative of EMMPRIN by ELISA

An enzyme immunoassay was developed for the quantification of EMMPRIN in BAL fluid. The wells of microtiter plates (Immulon #2; Dynatech Laboratories, Inc., Chantilly, VA) were coated overnight by incubation at room temperature with 1 μg/ml of goat polyclonal antibody raised against recombinant extracellular domain of human EMMPRIN (R&D Systems, Abingdon, UK). After three washes with wash buffer (0.05% Tween 20 in phosphate-buffered saline [PBS], pH 7.4), the plate was blocked by PBS containing 1% bovine serum albumin (BSA), 5% sucrose, and 0.05% NaN₃ and was incubated at room temperature for a minimum of 1 hour. For the generation of a standard curve, recombinant human EMMPRIN (R&D Systems) was diluted with 0.1% BSA and 0.05% Tween 20 in TBS (pH 7.3) in polypropylene tubes to final concentrations of 1,000, 500, 250, 125, 62.5, 31.3, 15.6, and 7.8 pg/ml. The EMMPRIN used to establish the standard curve showed a single band at approximately 40 kDa by Western blotting with the primary antibody, using an enhanced chemiluminescence Western blotting analysis system (Amersham, Aylesbury, UK) as previously described (26) (Figure 1). The plate was then washed three times with wash buffer, and 100 μL of unconcentrated BAL fluid or standard were added per well, followed by incubation for 2 hours at room temperature. After three washes with wash buffer, the plate was incubated with 100 μL of biotinylated antieextracellular domain of human EMMPRIN antibody (R&D Systems) at 400 ng/ml for 2 hours at room temperature. Then the plate was washed three times with wash buffer and 100 μL of streptavidin horseradish peroxidase (R&D Systems), diluted according to the manufacturer’s direction, was added to each well. After 20 minutes, the plate was washed three times and incubated with 100 μL of a 1:1 mixture of H₂O₂ and tetramethylbenzidine (R&D Systems) in the dark, and the reaction was stopped with 1 M of sulfuric acid within 30 minutes. The absorbance values were determined at 450 nm using a microplate reader (Wallac 1,420, Turku, Finland). A linear response was obtained with EMMPRIN standards from 7.8 to 1,000 pg/ml (Figure 2A). The ELISA had an interbatch coefficient of variation of 8% (n = 9) and an intrabatch coefficient of variation of 14% (n = 10), thus providing precise and sensitive detection of EMMPRIN. All assays were done in duplicate, and the mean values were used. All BAL fluid samples were on the standard curve when measured unconcentrated.

To test the reliability and accuracy of the EMMPRIN ELISA, selected BAL fluids were spiked with 125, 250, 500, and 1,000 pg of recombinant EMMPRIN and then assayed for EMMPRIN content. As shown in Figure 2B, assays of spiked BAL fluid consistently reflect the sum of the EMMPRIN in the starting sample plus the EMMPRIN spike.

Immunohistochemistry

Lung tissue was obtained from nine male smokers at the time of lobectomy for removal of primary lung cancer. These included subjects with and without airflow obstruction by pulmonary function testing. The tissue specimens were fixed in 10% phosphate-buffered formalin and embedded in paraffin. Five-micrometer sections were deparaffinized in xylene and rehydrated with graded alcohols. Antigenic activity was retrieved by incubation in 10 mM of citrate buffer (pH 6.0) in a microwave for 5 minutes. After washing in PBS, the slides were processed for immunohistochemistry using a catalyzed signal amplification (CSA) kit (DAKO Japan, Kyoto, Japan) according to the manufacturer’s protocol. The primary antibody was anti-EMMPRIN monoclonal antibody (CHEMICON, Temecula, CA) diluted at 1:500 with PBS.

Quantitative Reverse Transcription-Polymerase Chain Reaction for EMMPRIN

Alveolar macrophages (AMs) recovered from BAL fluids were adjusted to 1 × 10⁶ per ml and plated on poly-l-lysine-coated plastic wells (Corning, NY) for 1 hour at 37°C in RPMI-1640 medium (GIBCO, Grand Island, NY). After two washes in PBS, the adherent cells were used for purification of total RNA with guanidium thiocyanate using an Isogen RNA extraction kit (Nippon Gene, Tokyo, Japan). Reverse transcription was performed in the presence of Maloney leukemia virus reverse transcriptase (Epitentre Technologies, Madison, WI), and...
5‘ exoribonuclease-based fluorescent polymerase chain reaction was performed using an ABI PRISM 7,700 Sequence Detector (PE Applied Biosystems, Foster City, CA) as described (33). Oligonucleotide primers for EMMPRIN were derived from exon 5 of the human EMMPRIN gene sequence (GenBank accession number: L20471) (34). The primers and probe for this quantification system designed to meet specific criteria by using Primer Express software (PE Applied Biosystems) were as follows: forward, 5’-ACCTGGGCCGCTCTGCTG-3’, reverse, 5’-TCGTAATGAAAGATGATGGTGACC-3’, and probe; 5’-FAM-CTTCCATGGCATTACGTGCGTGAAGT-TAMRA-3’. The predicted size of the amplified EMMPRIN DNA product was 83 bp, and specific amplification was confirmed by ethidium bromide staining of the polymerase chain reaction product on an agarose gel. Primers and a labeled probe for glyceraldehyde-3-phosphatase-dehydrogenase (GAPDH) cDNA as an endogenous control were purchased from PE Applied Biosystems (TaqMan human GAPDH control reagents). The GAPDH concentrations of the polymerase chain reaction product on an agarose gel. Primers and a labeled probe for glyceraldehyde-3-phosphatase-dehydrogenase (GAPDH) cDNA as an endogenous control were purchased from PE Applied Biosystems (TaqMan human GAPDH control reagents). The relative amount of EMMPRIN mRNA in the samples was normalized by GAPDH mRNA.

**Interstitial Collagenase (MMP-1)**

MMP-1 levels in BAL fluids were measured by a solid-phase enzyme immunoassay (MMP-1 Immunoassay Kit; CHEMICON) that recognizes the zymogen and active forms of MMP-1 as well as forms complexed with tissue inhibitor of metalloproteinase-1. Importantly, the assay does not recognize MMP-8, the collagenase expressed by neutrophils. The assay’s range of detection was 0.11–3.6 ng/ml. Because MMP-1 was not detected in any unconcentrated BAL fluid, the fluids were concentrated 15-fold using Centricon filters having a molecular weight cutoff of 10,000 (Amicon Inc., Beverly, MA). Each fluid was measured in duplicate, and the results were averaged.

**Statistical Analysis**

Results are expressed as mean ± SEM unless otherwise stated. Statistical analyses were performed on the data using one-factor analysis of variance among four groups and Student’s unpaired t test between two groups when appropriate. The Spearman’s rank correlation was calculated to assess the correlation between the data. In all tests, p values of less than 0.05 were considered statistically significant.

**RESULTS**

**Characteristics of the Subjects**

The subjects were classified into five groups according to smoking history and presence of emphysema on computed tomography scans (Table 1). There were no significant differences in age among the groups. Emphysema, as detected on computed tomography scans, was less than 25% of the total lung area in most subjects. There was a significant but weak correlation between the EMMPRIN level in BAL fluid and the number of AMs in BAL fluid (n = 81, p < 0.01, r = 0.43) (Figure 4).

**EMMPRIN in BAL Fluids**

EMMPRIN was detected by ELISA in unconcentrated BAL fluid from all subjects. The EMMPRIN levels were significantly elevated in former and current smokers (175 ± 15 pg/ml SEM and 315 ± 20, respectively, compared with 31 ± 7 pg/ml in lifelong never-smokers) (Figure 3). However, the levels were not different between the subjects with and without emphysema among former and current smokers. There was a significant but weak correlation between the EMMPRIN level in BAL fluid and the number of AMs in BAL fluid (n = 81, p < 0.01, r = 0.43) (Figure 4).

**Localization of EMMPRIN in Smokers’ Lung**

By immunohistochemistry, EMMPRIN was found predominantly in AMs, bronchiolar epithelium, and bronchial glands in current smokers’ lungs. It was present diffusely in the cytoplasm of AMs and bronchial glands (Figures 5b and 5d) and was concentrated at the apices of bronchiolar epithelial cells (Figure 5c). In contrast, EMMPRIN was weakly seen in AM and was barely detectable in airways in lung tissue from lifelong never-smokers (Figure 5a).

**EMMPRIN mRNA in AMs**

EMMPRIN mRNA relative to GAPDH mRNA was determined in 21 subjects, including 7 never-smokers and 14 current smokers, including 5 with emphysema. EMMPRIN mRNA/GAPDH mRNA in AM in current smokers with emphysema was increased compared with the others, although it did not reach statistical significance because of the small number of subjects tested (Figure 6). There was a positive but weak relationship between the EMMPRIN concentration in BAL fluid and EMMPRIN mRNA levels in AMs (n = 21, p < 0.05, r = 0.43).

**MMP-1**

MMP-1 was not detectable by immunoassay in concentrated BAL fluids from 7 never-smokers but was measurable in concentrated fluids in seven of 36 current smokers, including three with emphysema (Figure 7).

**DISCUSSION**

EMMPRIN stimulates the production of MMPs by mesenchymal cells *in vitro*, including MMP-1, MMP-2, MMP-3, MMP-9, and MMP-14 (6–8, 35). It also induces the expression of MMPs by cells in vivo. For example, human breast cancer cells transfected with EMMPRIN cDNA injected into mammary fat pads of athymic mice have increased expression of MMP-2 and MMP-9 and are more tumorigenic and invasive than control plasmid-transfected cancer cells (8). MMP-1, and possibly other MMPs, binds to EMMPRIN on tumor cells, an effect that may facilitate MMP activity (36). EMMPRIN has been found to interact with cells via a hemo-

**TABLE 1. CHARACTERISTICS OF SUBJECTS**

<table>
<thead>
<tr>
<th></th>
<th>Former Smokers</th>
<th>Current Smokers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Never-smokers</td>
<td>Emphysema (+)</td>
</tr>
<tr>
<td>Number of subjects</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>Age, yr</td>
<td>64 ± 3</td>
<td>66 ± 3</td>
</tr>
<tr>
<td>Pack-year</td>
<td>34 ± 3</td>
<td>34 ± 2</td>
</tr>
<tr>
<td>FEV1/FVC, %</td>
<td>84 ± 2</td>
<td>79 ± 2</td>
</tr>
</tbody>
</table>

* p < 0.05 vs. never-smokers.

**TABLE 2. BRONCHOALVEOLAR LAVAGE FLUIDS**

<table>
<thead>
<tr>
<th></th>
<th>Former Smokers</th>
<th>Current Smokers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Never-smokers</td>
<td>Emphysema (+)</td>
</tr>
<tr>
<td>Recovery rate, %</td>
<td>71 ± 4</td>
<td>52 ± 5</td>
</tr>
<tr>
<td>Albumin, mg/L</td>
<td>56 ± 10</td>
<td>51 ± 8</td>
</tr>
<tr>
<td>Total cells, ×10³/mL</td>
<td>13 ± 1</td>
<td>9 ± 2</td>
</tr>
<tr>
<td>Macrophages, %</td>
<td>81 ± 6</td>
<td>88 ± 2</td>
</tr>
<tr>
<td>Neutrophils, %</td>
<td>0 ± 0</td>
<td>1 ± 0</td>
</tr>
</tbody>
</table>

* p < 0.05 vs. never-smokers.

**TABLE 2. BRONCHOALVEOLAR LAVAGE FLUIDS**

<table>
<thead>
<tr>
<th></th>
<th>Former Smokers</th>
<th>Current Smokers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Never-smokers</td>
<td>Emphysema (+)</td>
</tr>
<tr>
<td>Recovery rate, %</td>
<td>71 ± 4</td>
<td>52 ± 5</td>
</tr>
<tr>
<td>Albumin, mg/L</td>
<td>56 ± 10</td>
<td>51 ± 8</td>
</tr>
<tr>
<td>Total cells, ×10³/mL</td>
<td>13 ± 1</td>
<td>9 ± 2</td>
</tr>
<tr>
<td>Macrophages, %</td>
<td>81 ± 6</td>
<td>88 ± 2</td>
</tr>
<tr>
<td>Neutrophils, %</td>
<td>0 ± 0</td>
<td>1 ± 0</td>
</tr>
</tbody>
</table>

* p < 0.05 vs. never-smokers.

Mean ± SE.
Figure 3. EMMPRIN concentrations in BAL fluids. EMMPRIN levels were significantly elevated in both former and current smokers (179 ± 17 pg/ml SEM and 319 ± 20, respectively, compared with 31 ± 7 in never smokers, p < 0.05), but the levels were not significantly different between the subjects with and without emphysema in each group (open circles, without emphysema; closed circles, with emphysema).

philic interaction predominantly through the first immunoglobulin domain (37). Also, EMMPRIN colocalizes with α3β1 and α6β1 integrins and can be cross-linked, suggesting an interaction with integrins (38).

Although induction of MMPs is clearly an activity of EMMPRIN, EMMPRIN may have other activities. Complete EMMPRIN deficiency in mice, produced by gene targeting, is associated with a high level of early embryonic lethality (39). Deficient mice that survive have poor growth and abnormalities of the reproductive and central nervous systems (40), and most die before 2 months of age with diffuse infiltration of the lungs with lymphocytes and granulocytes (39).

By Western blotting, EMMPRIN is detectable in BAL fluids from normal rats and mice and is increased in BAL fluids from rats with ventilator-induced lung injury (16) and mice with bleomycin-induced lung fibrosis (26). This study is the first to quantify EMMPRIN in BAL fluid and the first report of EMMPRIN in human BAL fluid. The ELISA that we have developed has enabled reproducible measurements of EMMPRIN in unconcentrated BAL fluid from never-smokers. The average concentration in these subjects is approximately 32 pg/ml. The concentration is approximately 10-fold higher among current smokers. Former smokers also have elevated levels, approximately fivefold higher than never-smokers despite not smoking for 1 year or longer before obtaining their BAL fluid, indicating that the mechanisms responsible for increased EMMPRIN associated with smoking persist.

The protein core of EMMPRIN is approximately 27 kD. Glycosylated forms are 43–66 kD (1), and the capacity to induce MMPs requires glycosylation (5, 37). The glycosylation state of EMMPRIN varies among tissues (40). In experimental lung injury, there are increased high molecular weight forms in addition to an increased quantity of EMMPRIN in the BAL fluid (16, 26). The EMMPRIN in smokers’ BAL fluid in this study also showed multiple molecular weights, corresponding to unglycosylated and glycosylated forms, resembling forms seen in experimentally induced lung injury in rodents and, therefore, might be expected to include EMMPRIN with the capacity to induce MMPs.

The molecular basis for upregulation of EMMPRIN expression in various situations, including the association with smoking, is not known. Likewise, the mechanisms by which EMMPRIN induces MMPs have not been fully established. Binding of Sp1 and Sp3 to an Sp1 element in the EMMPRIN promoter appears to be required for regulation of EMMPRIN gene expression in macrophages (41). The levels of Sp1 and Sp3, as well as their activation and binding, are affected by a variety of stimuli so...
that different factors may be involved in different pathologic situations. Intracellular actions of EMMPRIN that lead to MMP induction involve the mitogen-activated protein kinase p38 for MMP-1 (42), but other pathways, including arachidonate metabolism, also appear to be involved (43).

The presence of EMMPRIN in BAL fluid indicates that EMMPRIN can be dissociated from cells despite its presumed transmembrane orientation. Moreover, on Western blot, there is EMMPRIN corresponding to the full-length protein core, suggesting that release of EMMPRIN can occur without proteolytic cleavage. In bleomycin-induced lung injury, we observed that airway and alveolar epithelial cells were EMMPRIN mRNA positive, although EMMPRIN was prominent at fibroinflammatory sites that were essentially devoid of cells expressing EMMPRIN mRNA (26). These findings are consistent with the recent demonstration that breast cancer cells in culture release full-length glycosylated EMMPRIN that promotes release of MMP-2 from fibroblasts (7, 43). Other examples of EMMPRIN associated with cells that do not make the protein are peritumor fibroblasts (3). Collectively, the results from these various studies clearly indicate that biologically active EMMPRIN is not restricted to the cells in which it is produced.

Finding increased EMMPRIN in smokers’ BAL fluid raises the question of its cellular source. AMs appear to be one likely source, as EMMPRIN mRNA has been reported in AMs in emphysematous lung associated with cancer (44), and EMMPRIN is expressed by monocyte-derived macrophages (15). However, we did not detect differences in EMMPRIN mRNA in AMs between current and never-smokers. The regression analysis of EMMPRIN concentration against AM numbers in BAL fluid or EMMPRIN mRNA/GAPDH mRNA in AM also gave a poor correlation. It is still possible that synthesis of EMMPRIN in AM in current smokers and/or the increase of AM number in the lung in smokers may contribute to the elevation of EMMPRIN in smokers’ BAL fluid. Another possibility is that AM may be only one of several cell types involved in EMMPRIN production in smokers’ lungs. Basigin is expressed in epithelial tissues of fetal mouse lungs (2). EMMPRIN has been found immunohistochemically in ciliated cells of normal bronchi and bronchi affected by squamous cell carcinoma (3). Smoking is likely in association with these carcinomas. Other cell types also express EMMPRIN, such as fibroblast-like synovial cells (10), but there is no indication that mesenchymal cells are the source of EMMPRIN in smokers’ lungs.

MMPs have been implicated in parenchymal lung destruction and repair processes of emphysema and diverse other pulmonary diseases (18, 19). Previously, we reported elevated MMP-9 and MMP-8 in BAL fluids from smokers with emphysema compared with smokers without emphysema (29), but these MMPs were likely derived from neutrophils, at least in part, as some of the MMP-9 was complexed with lipocalin, a neutrophil product, and MMP-8 is primarily a neutrophil enzyme (45). However, there are data linking MMP-1, an enzyme that is not produced by neutrophils, to emphysema. D’Armiento and coworkers generated transgenic mice that expressed human MMP-1 in their lungs, and these animals developed airspace enlargement resembling emphysema (46). Immunohistochemically, MMP-1 has been localized in AM, bronchial epithelial cells, and alveolar type II cells in emphysema (30, 47), and AMs from patients with emphysema produce elevated quantities of MMP-9 and collagenase activity in culture media (27).

Therefore, in this study, we focused on the association between MMP-1 and EMMPRIN. Seven current smokers, including three with emphysema, had detectable levels of MMP-1 in 15-fold concentrated BAL fluids, whereas none of the concentrated BAL fluids from never-smokers showed detectable levels of MMP-1, as reported previously (48). It should be noted that emphysema severity was low in the subjects scored as emphysema in this study. However, neither MMP-1 nor EMMPRIN in BAL fluids separated former or current smokers with emphysema from smokers without emphysema. Perhaps the MMP-1 (and EMMPRIN) levels would be higher in individuals with more advanced disease comparable to the individuals studied by Imai and colleagues (30). Although our focus in this study has been directed to the relationship of EMMPRIN to chronic obstructive pulmonary disease, one might speculate that increased EMMPRIN in smokers’ lungs may have other effects such as promoting invasion of primary lung tumor cells considering the association between EMMPRIN and invasiveness of other tumor cells.

In summary, we have observed that smoking is associated with increased EMMPRIN in BAL fluid and that the increase persists for a long period after smoking cessation. AMs appear to be one source of the increased EMMPRIN, as EMMPRIN mRNA is increased in some smokers’ AMs. Bronchial epithelial cells also show increased EMMPRIN in smokers and may be another source of increased EMMPRIN in BAL fluid. Our findings support the possibility that EMMPRIN has a role in the pathogenesis of emphysema in smokers.

Acknowledgment: The authors thank Ms. Yoko Suzuki for excellent technical assistance and the technical support staff of R&D Systems for advice in the development of the ELISA for EMMPRIN.

References


